Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy

Background: Chronic obstructive pulmonary disease (COPD) increases the risk of severe respiratory syncytial virus (RSV)-related disease. This analysis evaluated the potential public health impact and cost-effectiveness of RSV vaccination with a single dose of adjuvanted RSVPreF3 vaccine over five years in people aged 60-74 years with COPD in Italy. Research design and methods: A static multi-cohort Markov model estimated RSV-related events, costs, and quality-adjusted life-years (QALY) over five years in people aged 60-74 years with COPD in Italy vaccinated with one dose of adjuvanted RSVPreF3, versus no vaccination. Vaccine efficacy and waning data were based on AReSVi-006 Phase III clinical trial results. Other input data came from published literature and official databases. Sensitivity analyses were conducted. Results: A single dose of adjuvanted RSVPreF3 vaccine (75% coverage) was projected to reduce RSV-related acute respiratory infections by 29% and RSV-related hospitalizations and deaths by 38% among patients with COPD aged 60-74 years in Italy. The incremental cost-effectiveness ratio (health system perspective) was €1,306/QALY. Conclusions: These results indicated that a single dose of adjuvanted RSVPreF3 vaccine in patients with COPD aged 60-74 years in Italy is a cost-effective preventive option that could potentially reduce RSV-related disease burden and costs over five years.